Avidity Biosciences Inc (RNA) Stock Price, Quote & News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stag...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 401 7900

Website: www.aviditybiosciences.com

Address:

10578 Science Center Drive, Suite 125, San Diego, United States

AtomicAIerts Dec. 5 at 6:58 AM

$RNA AtomicAlerts Scalp Alert Direction: SHORT Entry: $71.55 TP1: $70.85 | TP2: $70.15 | TP3: $69.45 Stop Loss: $72.15 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 2:09 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $70C Entry: 1.98 Exit: 3.74 Return: +89.24% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:41 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $70C Entry: 1.98 Exit: 3.74 Return: +89.24% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

vic_li38 Dec. 4 at 2:32 PM

$RNA push!

0 · Reply

BillionerOfKing Dec. 4 at 10:15 AM

$RNA Current Stock Price: $71.58 Contracts to trade: $70 RNA Dec 19 2025 Call Entry: $1.71 Exit: $2.59 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Iightning Dec. 4 at 4:24 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $70C Entry: 1.98 Exit: 2.95 Return: +49.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

wwmeinc Dec. 3 at 6:15 PM

$RNA ......We might be getting close for the Co. to finalize a Date of Record....so far that last SEC filing(Nov.24/25) was just a preliminary release....nothing 'set in stone' in regards to vote,etc...Choice now to sell and move capital elsewhere or hang-tight for the record date and SpinOut news/shares....after the vote of course...glta

0 · Reply

Iightning Dec. 3 at 8:52 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $50C Entry: 21.70 Exit: 33.54 Return: +54.58% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:42 PM

$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥

0 · Reply

wwmeinc Dec. 2 at 1:38 AM

$VKTX $IOVA $RNA ....A 'drawback' of receiving an CVR.....courts will now decide if Bristol played 'fast and losse' with the concept....this is why cash is always king...saves any questionable moves by the buyer from coming to bear on shareholders waiting to get paid for a future event...data delay.etc...A promisary note that really is only backed up by the good faith of the issuer.....the courts will decide if this/was the case though...should be an interesting tale though...glta https://www.reuters.com/world/bristol-myers-must-face-67-billion-lawsuit-over-delayed-cancer-drug-us-judge-2025-12-01/

1 · Reply

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH INSM LITE MP

Nov 19, 2025, 9:13 AM EST - 15 days ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nov 10, 2025, 4:05 PM EST - 24 days ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Oct 31, 2025, 9:44 AM EDT - 4 weeks ago

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Oct 28, 2025, 5:13 PM EDT - 5 weeks ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR NVS PAGP

Oct 27, 2025, 8:05 PM EDT - 5 weeks ago

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Oct 27, 2025, 5:12 PM EDT - 5 weeks ago

Why Avidity Biosciences Stock Blasted 42% Higher Today

Oct 27, 2025, 2:52 PM EDT - 5 weeks ago

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

NVS

Oct 27, 2025, 12:31 PM EDT - 5 weeks ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 10:22 AM EDT - 5 weeks ago

Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 8:16 AM EDT - 5 weeks ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

NVS

Oct 27, 2025, 6:54 AM EDT - 5 weeks ago

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

HSBC NVS

Oct 27, 2025, 6:29 AM EDT - 5 weeks ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

NVS

Oct 27, 2025, 4:59 AM EDT - 5 weeks ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS

Oct 26, 2025, 5:33 PM EDT - 5 weeks ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

NVS

Oct 26, 2025, 3:46 PM EDT - 5 weeks ago

Novartis to acquire Avidity Biosciences for about $12B

NVS

Oct 26, 2025, 3:29 PM EDT - 5 weeks ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS

Oct 26, 2025, 1:07 PM EDT - 5 weeks ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS

Oct 26, 2025, 1:07 PM EDT - 5 weeks ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

NVS

Oct 26, 2025, 1:00 PM EDT - 5 weeks ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

NVS

Oct 26, 2025, 12:26 PM EDT - 5 weeks ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

NVS

Oct 26, 2025, 11:09 AM EDT - 5 weeks ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

NVS

Oct 16, 2025, 9:00 AM EDT - 7 weeks ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Oct 13, 2025, 9:00 AM EDT - 7 weeks ago

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Oct 6, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Sep 15, 2025, 4:01 PM EDT - 2 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 11, 2025, 7:56 PM EDT - 3 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 11, 2025, 2:36 PM EDT - 3 months ago

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota

Sep 11, 2025, 8:08 AM EDT - 3 months ago

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LOVE VERI

Sep 10, 2025, 5:40 PM EDT - 3 months ago

Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)

Sep 10, 2025, 4:01 PM EDT - 3 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 7:00 AM EDT - 3 months ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Sep 8, 2025, 4:45 PM EDT - 3 months ago

Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 10:15 PM EDT - 3 months ago

Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:37 AM EDT - 3 months ago

Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 9:00 AM EDT - 3 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 7, 2025, 6:19 PM EDT - 4 months ago

Avidity (RNA) Q2 Revenue Jumps 88%

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 11:41 AM EDT - 4 months ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Jul 28, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 23, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Jun 11, 2025, 9:00 AM EDT - 6 months ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Jun 9, 2025, 7:01 AM EDT - 6 months ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Jun 9, 2025, 7:00 AM EDT - 6 months ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

May 21, 2025, 4:05 PM EDT - 7 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 4:05 PM EDT - 7 months ago

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

AtomicAIerts Dec. 5 at 6:58 AM

$RNA AtomicAlerts Scalp Alert Direction: SHORT Entry: $71.55 TP1: $70.85 | TP2: $70.15 | TP3: $69.45 Stop Loss: $72.15 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 2:09 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $70C Entry: 1.98 Exit: 3.74 Return: +89.24% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:41 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $70C Entry: 1.98 Exit: 3.74 Return: +89.24% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

vic_li38 Dec. 4 at 2:32 PM

$RNA push!

0 · Reply

BillionerOfKing Dec. 4 at 10:15 AM

0 · Reply

Iightning Dec. 4 at 4:24 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $70C Entry: 1.98 Exit: 2.95 Return: +49.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

wwmeinc Dec. 3 at 6:15 PM

0 · Reply

Iightning Dec. 3 at 8:52 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RNA Contract: Dec 19 $50C Entry: 21.70 Exit: 33.54 Return: +54.58% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:42 PM

$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥

0 · Reply

wwmeinc Dec. 2 at 1:38 AM

1 · Reply

Iightning Dec. 1 at 10:36 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RNA **Contract:** Dec 19 $70C **Entry:** 2.01 **Exit:** 3.02 **Return:** **+49.87% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

quickaspeter Nov. 26 at 4:35 PM

$RNA $SRPT $TSHA Amazing…❤️💥🚀💰

0 · Reply

wwmeinc Nov. 26 at 3:25 PM

$VKTX ...For sure.....and with everybody and their mothers and grandparents all looking for that next buy-out candidiate after the great drama PFE/MTSR/NVO gave the mkt/sector....Brian is most likely kicking out the low-ballers as we speak...once they get into office though. What is a bit interesting, is this 'cone of silence' that has dropped on these bidders....Guessing, the lawyers have laid down the law to all employees/bankers/advisors, which in turn shuts out those pesky fin'l reporters looking for the next $RNA scoop...hmmm....just need one...just one to slip under this cone...;) Oh well...just a matter of when not if we get this release...Thanks. glta "In summary, while NVO and LLY currently dominate the market with effective, once-weekly injectable treatments, VKTX is a potential disruptor due to its comparable efficacy data in earlier trials and the potential for a more convenient, less frequent dosing schedule"

2 · Reply

Iightning Nov. 26 at 1:22 AM

1ightning® Options Trade Alert (Actionable) | Buy $RNA Dec 19 $75 Call | Enter: $0.05 Exit: $0.06 | Profit: 28.43% ROI | https://1ightning.com

0 · Reply

wwmeinc Nov. 25 at 5:54 PM

$RNA ...Noticed how the two Investment bankers/advisors(Barclays and Goldman).....used the WS analysts price targets as a bit of info/data gathering when calculating a 'value' for Sarah/BOD to bring to shareholders....with the final being $72 cash....just saying...and a SpinCo....with its $1.58 handle(pre-listing though)....w/$270M in the bank to boot...that being said...those 350+ pages got to the eyes last night ;) In the end...cash is king, bigtime! Thanks. glta ***Those FT finance reporters....they really deserve all the credit, for my case at least. If I ever looked or had $RNA in one of the watchlists...I cannot remember if I actually ever "re-visited" them before those FT reporters dropped the rumour....still, DD is a requirement...as nothing is guaranteed with biotech's.

0 · Reply

JFais Nov. 25 at 5:07 PM

$RNA $MDGL Congrats on the W @JoseRestonVA Respect the patience & risk mgmt 👏

0 · Reply

dogDazeSummer Nov. 25 at 4:17 PM

Fascinating play by play released SEC filings by and between $RNA and $NVS from July until Ovorvet. Recall the chemo centrix back and forth w $AMGN and realized these deals hinge on 1-2 key attributes. $IFRX $AZN

1 · Reply

Iightning Nov. 25 at 11:29 AM

1ightning® Options Trade Alert (Actionable) | Buy $RNA Dec 19 $75 Call | Enter: $0.05 Exit: $0.06 | Profit: 28.43% ROI | https://1ightning.com

0 · Reply

dgbio Nov. 25 at 6:36 AM

$RNA Reading merger proxy: • There were several other buyers expressing interest but also saying they need more time. • The deal is done via shareholder vote and not by tender which is faster. • Avidity is able 'in certain circumstances, to furnish information to and conduct negotiations with a third party regarding a bona fide written, unsolicited, alternative Acquisition Proposal (as defined in the section of this proxy statement entitled “The Merger Agreement—Certain Definitions” beginning on page 110) that the Board determines in good faith, after consulting with its outside legal counsel and financial advisors, constitutes or could reasonably be expected to lead to a Superior Proposal'. =>Superior offer remains possible.

0 · Reply

Iightning Nov. 25 at 12:24 AM

1ightning® Options Trade Alert (Actionable) | Buy $RNA Dec 19 $75 Call | Enter: $0.05 Exit: $0.06 | Profit: 28.43% ROI | https://1ightning.com

0 · Reply

dgbio Nov. 25 at 12:10 AM

$RNA Reading merger proxy: first proposal - $52, second proposal - $60, third proposal - $70, final proposal - $72 + SpinCo. Did a financing because Novartis was conditioning proposal on certain DD results. Said no to this, cut Novartis off the data room and did $500M financing. Boyce is really good. Whatever she does next, I want a share in it.

0 · Reply

Night_Owl_Biotech Nov. 24 at 10:34 PM

@outlawinvestor1 Hey man $RNA filed its 14A today. As you probably know, RNA was acquired for roughly $12B. I have not done the work yet but it appears the enterprise value is roughly $10B (but I need to do the math). Gross margins are forecast to be in the mid-80s (85% at peak). The RNA EV appears to be, more or less, 1X peak sales. I have to leave for the day. I'll compare to the oncology companies tomorrow morning. $XBI $IBB $NBI FYI only.

1 · Reply

Market Cap	10.78B
Revenue (ttm)	10.90M
Net Income (ttm)	-322.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,956.88%
Debt to Equity Ratio	0.00

Volume	2,514,100
Avg Vol	5,370,926
Day's Range	N/A - N/A
Shares Out	150.68M
Stochastic %K	81%
Beta	0.90
Analysts	Sell
Price Target	$73.25